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ABSTRACT Mallory-Denk bodies (MDBs) are hepato-
cyte inclusions that are associated with poor liver disease
prognosis. The intermediate filament protein keratin 8 (K8)
and its cross-linking by transglutaminase-2 (TG2) are essen-
tial for MDB formation. K8 hyperphosphorylation occurs in
association with liver injury andMDB formation, but the link
between keratin phosphorylation and MDB formation is
unknown. We used a mutational approach to identify K8
Q70 as a residue that is important for K8 cross-linking to
itself and other liver proteins. K8 cross-linking is markedly
enhanced on treating cells with a phosphatase inhibitor and
decreases dramatically on K8 S74A orQ70Nmutation in the
presence of phosphatase inhibition. K8Q70 cross-linking, in
the context of synthetic peptides or intact proteins trans-
fected into cells, is promoted by phosphorylation at K8 S74
or by an S74D substitution and is inhibited by S74A muta-
tion. Transgenic mice that express K8 S74A or a K8 G62C
liver disease variant that inhibits K8 S74 phosphorylation
have amarkedly reduced ability to formMDBs.Ourfindings
support a model in which the stress-triggered phosphoryla-
tion of K8 S74 induces K8 cross-linking by TG2, leading to
MDB formation. These findingsmay extend to neuropathies
and myopathies that are characterized by intermediate fila-
ment-containing inclusions.—Kwan, R., Hanada, S., Harada,
M., Strnad, P., Li, D. H., Omary, M.B. Keratin 8 phosphor-
ylation regulates its transamidation and hepatocyte Mallory-
Denk body formation. FASEB J. 26, 2318–2326 (2012).
www.fasebj.org
Key Words: intermediate filaments  steatohepatitis  transglut-
aminase 2
Several human liver diseases, particularly steato-
hepatitis but also other entities, such as viral hepatitis,
are associated with prominent intracytoplasmic inclu-
sions termed Mallory-Denk bodies (MDBs) (1, 2). The
presence of MDBs serves as a poor prognostic marker
in patients with liver disease (3–5). MDBs are primarily
composed of the intermediate filament (IF) proteins
keratins 8 and 18 (K8/K18), as well as ubiquitin (Ub)
and the Ub-binding protein p62 (1, 2, 6). K8 and K18
exist as obligate noncovalent heteropolymers in a 1:1
stoichiometry and form cytoplasmic filaments that pro-
vide structural support and cytoprotective functions in
hepatocytes (2).
MDB formation can be induced in mice through
chronic feeding with griseofulvin or 3,5-diethoxycar-
bonyl-1,4-dihydrocollidine (DDC) (7, 8). These mouse
models, coupled with the use of transgenic mice that
overexpress K8 and/or K18 and mice with null alleles
of these genes, have helped elucidate the molecular
requirements for MDB formation. Therefore, it is now
clear that K8 is particularly important for MDB forma-
tion, because K8-null mice do not develop MDB in
response to DDC feeding, in contrast to K18-null
animals, which develop spontaneous MDBs on aging
(9, 10). In addition, transgenic mice that overexpress
K8 develop MDBs spontaneously (without DDC feed-
ing) on aging, while K18-overexpressing mice are
highly resistant to MDB formation despite DDC feeding
(11, 12). Thus, an increase in hepatocyte K8 levels
relative to K18, which occurs in the context of some
forms of liver injury, is critical for MDB formation.
Biophysical studies further support the importance of
K8 in MDB formation. For example, K8, but not K18,
acquires a cross--sheet structure (a defining feature of
amyloid inclusion proteins) on MDB formation, sug-
gesting that K8 conformational changes and aggrega-
tion are likely drivers of MDB formation (13–16).
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In MDBs, both K8 and K18 are covalently linked to
other MDB-constituent proteins by transglutaminases
(TGs), calcium-dependent transamidating enzymes
that cross-link proteins via amide bonds between the
ε-amino group of lysine and the -carboxyl group of
glutamine (17–19). TG2 is the most abundant TG
activity in the liver and has been implicated in the
cross-linking of various inclusion-constituent proteins,
including mutant huntingtin in Huntington disease
(20–24) and -synuclein in Parkinson disease (25, 26).
Notably, K8 is the preferred substrate for TG2 as
compared with K18, and the TG2-mediated cross-link-
ing of K8 to other MDB-constituent proteins is essential
for MDB formation since TG2-null mice are highly
resistant to DDC-induced MDB formation (27). The
potent TG2 inhibitor KCC009 prevents DDC-induced
mouse hepatomegaly but not MDB formation, but it is
unclear whether KCC009 can inhibit intracellular TG2
activity in vivo (28), which is required for MDB forma-
tion. Phosphokeratins (e.g., K8 pS24, pS74, and pS432),
particularly K8 pS74, are prominent within human and
mouse MDBs (29), but the connection between keratin
phosphorylation, cross-linking, and MDB formation is
unknown.
In the current study, we first focused on identifying K8
transamidation sites, given the importance of K8 transami-
dation in MDB formation. This led us to identify K8 Q70
as a preferential transamidation site in K8 and to show
that K8 S74 phosphorylation not only promotes keratin
cross-linking but is also critical for MDB formation in
mice. These findings provide the first direct link between
keratin phosphorylation and MDB formation and charac-
terize the first K8 glutamine transamidation site.
MATERIALS AND METHODS
Mice
Three transgenic mouse lines that overexpress K8 wild type
(WT), K8 G62C, and K8 S74A (all in an FVB genetic
background) were described previously (30). Genotyping was
performed by PCR screening using mouse tail genomic DNA
as described previously (30). All mice received humane care
in compliance with the U.S. Department of Health and
Human Services Guide for the Care and Use of Laboratory
Animals, and their use was approved by the University Com-
mittee on Use and Care of Animals (UCUCA) at the Univer-
sity of Michigan.
DDC treatment and tissue harvesting
Mice were fed a powdered chow (Formulab Diet 5008; Deans
Animal Feeds, Redwood City, CA, USA) containing 0.1%
DDC (Sigma-Aldrich, St. Louis, MO, USA) for 6 wk, which
results in readily detectable MDBs in the K8 WT-overexpress-
ing mice (11, 12). At the conclusion of the feeding period,
mice were sacrificed by CO2 inhalation, and tissue harvesting
was performed as described previously (11).
Antibodies
The following antibodies were used: rabbit anti-mouse/hu-
man (h) TG2 and mouse anti-hK8 mAb (M20 and TS1; Lab
Vision, Fremont, CA, USA), rat anti-mouse/human K8 mAb
(Troma I; Developmental Studies Hybridoma Bank, Iowa
City, IA, USA); rabbit anti-K8/18 Ab-8592; rabbit anti-K18
Ab-4668; and mouse anti-Ub mAb (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA).
Immunofluoresence staining
Livers were sectioned and fixed with 20°C acetone (10
min). Staining was carried out as described previously (31).
Images were obtained using a 60/NA 1.40 water lens or a
20/NA 1.40 lens combined with a confocal microscope
(Zeiss 510 Meta, Carl Zeiss, Thornwood, NY, USA), and
acquired by LaserSharp software (Carl Zeiss, Thornwood, NY,
USA). For double-labeling analyses, images were acquired
sequentially using separate excitation wavelengths of 488 nm
for fluorescein thiocyanate or Alexa 488 and 568 nm for
Texas red, and then merged.
Gel electrophoresis and immunoblotting
Liver tissues were lysed in homogenization buffer (0.187 M
Tris-HCl, pH 6.8; 3% SDS; 5 mM EDTA). Homogenates were
diluted with 4 reducing Laemmli sample buffer, and equal
amounts of protein were applied to SDS-PAGE, followed by
blotting and visualization of the immune-reactive species
using Western Lightning-ECL (GE Healthcare, Piscataway,
NJ, USA).
Histological analysis
Hematoxylin and eosin (H&E)-stained sections were assessed
for the histological criteria of hepatocyte ballooning, MDB
formation, and ductal proliferation using 0–3 scoring (0,
none; 1, rare; 2, frequent; 3, abundant). Scheuer’s criteria
were applied for the analysis of liver inflammation and
necrosis (32).
In vitro analysis for cross-linking of K8
Baby hamster kidney (BHK) cells were transfected with an
equal amount of human K8 WT, K8 Q7N, K8 Q70N, K8 S74A,
K8 S74D, K8 Q85N, K8 Q85N Q90N, or Q408N plasmid
together with K18 WT using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA). In some cases, cells were treated with 1
M okadaic acid (OA; Enzo Life Sciences, Farmingdale, NY,
USA). After 48 h, the transfected cells were lysed in Nonidet
P-40 buffer [1% Nonidet P-40, 1 PBS (pH 7.4), 5 mM EDTA,
and protease inhibitor cocktail from Sigma-Aldrich], and
equal volumes of extracts were incubated with 3.5 g/ml
recombinant TG2 in the presence of 15 mM CaCl2 (37°C).
The reaction was quenched by adding 4 reducing Laemmli
sample buffer, followed by gel electrophoresis and immuno-
blotting.
Hepatocyte isolation
Male mice were used. After anesthesia, the liver was first
perfused with a buffer containing Hanks’ balanced salt solu-
tion that includes 0.5 mM EGTA, 5.5 mM glucose, and 1%
penicillin-streptomycin. This was followed by perfusion with a
collagenase IV (Worthington, Lakewood, NJ, USA) contain-
ing buffer that includes Hanks’ balanced salt solution with 1.2
mM CaCl2 and 5.5 mM glucose, 1% penicillin-streptomycin.
The cells were then dispersed in William’s medium E (WME),
filtered through a 70-m cell strainer, pelleted (500 rpm, 2
min, 4°C), and washed twice before plating at a density of 5 
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105 cells/ml on collagen I-coated plates (BD BioCoat; BD
Biosciences, Bedford, MA, USA) in WME supplemented with
10% FBS and 1% penicillin-streptomycin. After 1 h, the
culture medium was replaced, and cells were allowed to
attach for another 12 h (37°C, 5% CO2) before OA treat-
ment. All of the solutions were prewarmed to 37°C before
use.
In vitro cross-linking of K8 peptides to mouse liver proteins
Biotin-tagged peptides spanning K8 Ala65 to Lys81 were
synthesized using standard methods (AnaSpec, Fremont, CA,
USA). The synthesized peptides represented K8 WT, pS74
(phosphopeptide), and D74 (phosphomimetic peptide). As a
glutamine control peptide, a biotin-tagged K8 peptide con-
taining Q85 (K8 Q85) was generated as a negative control.
Peptides (1.4 mM) were incubated (37°C) with Nonidet P-40
lysates from normal mouse livers, followed by the addition of
TG2 (3.5 g/ml) in the presence of 15 mM CaCl2 (2 h). The
reaction was quenched by adding 4 reducing Laemmli
sample buffer, followed by gel electrophoresis and blotting
using streptavidin-HRP (KPL, Gaithersburg, MD, USA).
Stable Chinese hamster ovary (CHO) cell line selection and
MG132/peroxide treatments
CHO cells were cultured in DMEM supplemented with 10%
FBS and 1% penicillin/streptomycin. Cells were transfected
with the following pcDNA 3 (Invitrogen) constructs: WT K18
plus either WT K8, Q70N K8, or Q85N K8. Stably transfected
cells were selected using 600 g/ml geneticin. Clones ex-
pressing K18 and K8 were isolated by limiting dilution and
tested for keratin expression and filament organization by
immunofluorescence staining. MG132 (5 M; EMD Chemi-
cals, Gibbstown, NJ, USA), and H2O2 (1.2 mM) stock solu-
tions were used as specified in the figure legend.
Statistical analysis
Values are shown as means  sd. Student’s t test and
Spearman rank correlation were used, with P  0.05 being
considered significant.
RESULTS
Identification of Q70 as a human K8 transamidation
site
We used site-directed mutagenesis to identify glu-
tamine and lysine residues in K8 as potential TG2 target
sites. For this purpose, K8 Gln¡Asn and Lys¡Arg
mutants at potential transamidation sites were gener-
ated in the head and tail domains of K8 (Fig. 1A). We
focused on head and tail domains because they are the
domains that include hitherto well-characterized post-
translational modifications, while modifications in the
rod domains of IF proteins are generally uncommon
(33). BHK cells, which do not express endogenous K8
or K18, were cotransfected with WT or mutant K8
and WT K18. Efficient expression of K8 for the Q¡N
mutants (Fig. 1B) and K¡R mutants (Supplemental
Fig. S1) was confirmed. We then developed an in vitro
TG assay to compare the TG2-mediated cross-linking
of WT K8 with that of the Q¡N and K¡R mutants.
Figure 1. K8 Q70N mutation inhibits TG2-mediated cross-linking. A) Sche-
matic of the human K8 protein domains showing the location of glutamine (Q)
and lysine (K) residues in the non--helical K8 head and tail domains. B)
Extracts from untransfected BHK cells and cells transfected with WT K18 plus
WT K8 or the K8 mutants: Q7N, Q70N, Q85N, Q85N/Q90N, and Q408N were
separated on SDS-PAGE then blotted with antikeratin antibodies. C) Extracts
from BHK cells transfected with WT K18 plus WT K8 were treated with the
indicated concentrations of TG2 at 37°C for 5, 15, 30, and 60 min. Reactions
that lacked either TG2 or calcium were incubated at 37°C for 30 min, then
quenched using 4 Laemmli sample buffer and blotted with anti-K8 antibod-
ies. Arrows highlight the K8-containing cross-links that form in TG2- and
calcium-dependent manners. D) Extracts of the cell transfectants were treated
with TG2 for 15 min (37°C) or left untreated. Reaction mixtures were
separated using SDS-PAGE then blotted with antibodies to K8. Arrows indicate
K8-containing cross-links whose formation decreased dramatically on K8 Q70N
mutation.
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As shown in Fig. 1C, treatment of Nonidet P-40
extracts of K8-expressing BHK cells with increasing
amounts of recombinant TG2 or with increasing
incubation times resulted in increasing amounts of
K8 cross-linking that is detected at the top of the
stacking gel or at the interface of the stacking and
resolving gel (Fig. 1C). K8 cross-linking is dependent
on both TG2 and its cofactor calcium, as no cross-
linking was observed without both TG2 and calcium
in the reaction (Fig. 1C).
After establishing the in vitro transamidation assay con-
ditions, we compared TG2-mediated transamidation of
WT K8 to that of K¡R and Q¡N mutant K8 proteins.
The K¡R K8 mutant proteins exhibited relatively similar
levels of K8 cross-linking after TG2 treatment (Supple-
mental Fig. S1B), which is consistent with reports that
TG2 substrate specificity is determined primarily by the
amino acid sequence flanking the glutamine residues
rather than the lysine residues of potential substrates (34).
In contrast, all Q¡N mutant K8 proteins had a level of
cross-linking that is similar to WT K8 except for K8 Q70N,
which exhibited a significant impairment in K8 cross-
linking (Fig. 1D, arrows).
The findings of the in vitro transamidation assay
suggest that Q70 in K8 is important for the TG2-
mediated cross-linking of K8, and potentially for subse-
quent MDB formation. To test this hypothesis in the
context of live cells, CHO cells, which do not express
endogenous keratins, were stably transfected with WT
K8, Q70N K8, and Q85N K8, and clones expressing
these proteins were isolated. MDB formation is initiated
in response to increased oxidative stress and the accu-
mulation of unfolded or damaged proteins within the
cell (2, 35–39). Also, oxidative stress has been shown to
increase TG2 activity (40–42). To mimic these condi-
tions in cell culture, WT-, Q70N-, and Q85N K8-
expressing clones were treated with H2O2 and/or the
proteasome inhibitor MG132. Such treatments of the
WT or Q85N K8 clones caused the appearance of a
highly cross-linked species of K8 (Fig. 2A), while the
Q70N mutation prevented the appearance of cross-
linked K8 after H2O2  MG132 treatments, despite the
somewhat higher level of Q70N K8 relative to WT and
Q85N clones after treatment (Fig. 2A).
K8 site-specific phosphorylation enhances
TG2-mediated K8 cross-linking
The results shown in Figs. 1D and 2A suggest that Q70
in K8 is a TG2 substrate. Notably, Q70 is in close
Figure 2. K8 S74 phosphorylation enhances Q70 transamidation in vitro. A) CHO cells stably transfected with K8 WT, K8 Q85N,
and K8 Q70N were treated with vehicle or with 5 MMG132 and/or 1.2 mM H2O2 for 24 h. Cells were lysed in homogenization
buffer, and extracts were blotted with antibodies to TG2 (middle panel) or to K8 (upper and lower panels, with lower panel
being a lighter exposure to show the relative intensity of the K8 monomeric species). B) Biotinylated peptides K8 WT, K8 pS74,
and K8 S74D (all 3 peptides contain Q70 and are identical except for having S74, pS74, and D74) and the glutamine control
peptide K8 WT-Q85 (see Table 1 for sequences) were incubated (37°C) with Nonidet P-40 lysates from normal mouse liver and
TG2 (3.5 g/ml) in the presence of 15 mM CaCl2 for 2 h. Three independent liver lysates were tested. Reaction was quenched
by adding 4 reducing sample buffer, followed by separation using SDS-PAGE, then immune blotting with streptavidin-HRP to
visualize liver proteins that became cross-linked to the biotinylated peptides. Arrow indicates biotinylated K8 peptide that
becomes cross-linked to liver proteins to generate high-molecular-weight species, aside from the range of other cross-linked
adducts.
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proximity to S74 in K8, which is not phosphorylated in
normal hepatocytes but becomes phosphorylated in
human and mouse MDBs (29) or on exposure of
epithelial cells and tissues to a wide range of stresses
(33). We compared the amino acid sequence flanking
Q70 with reported TG2 transamidation consensus se-
quences. One reported consensus sequence (34),
QXX	DP, is similar to the amino acid sequence flank-
ing Q70 (QSLLSP), except that there is a consensus
aspartate residue in the position that S74 occupies that
could mimic a phospho-S74. Therefore, we hypothe-
sized that S74 phosphorylation acts as a K8 cross-linking
switch that converts Q70 from a poor TG2 substrate
into a good one. We tested this hypothesis using
synthetic K8 biotinylated peptides (Table 1) that share
Q70 but include either S74, pS74, or D74, and also used
a K8 Q85-containing peptide as a control. As shown in
Fig. 2B, the pS74 and the phosphomimetic D74 pep-
tides are excellent TG2 substrates that are able to
cross-link with numerous mouse liver proteins as com-
pared with the WT (i.e., nonphospho-S74 K8) or K8
Q85N control peptides.
We then asked whether overall K8 hyperphosphory-
lation enhances its TG2-mediated cross-linking. For
this, we treated human colon carcinoma HT29 cells,
which express high levels of K8 and K18 (31), with the
phosphatase inhibitor OA and then tested the cell
extracts using an in vitro transamidation assay. OA
inhibits protein phosphatase (PP) 1, 2A, and 4–6, and
to a lesser extent PP 2B and 7 (43), and the treatment
of cells with this toxin results in hyperphosphorylation
at Ser and Thr residues (44). After 30 and 60 min of OA
treatment, K8 became markedly phosphorylated at S74,
as determined using a K8 pS74-specific antibody
(Fig. 3A). Furthermore, the addition of TG2 to HT29
extracts from untreated cells produced limited, if any,
TABLE 1. K8 biotinylated peptide sequences
Peptide Sequence
K8 WT AVTVNQSLLSPLVRRK-biotin
K8 pS74 AVTVNQSLLpSPLVRRK-biotin
K8 S74D AVTVNQSLLDPLVRRK-biotin
K8 WT-Q85 VDPNIQAVRTNERRRK-biotin
Gln and S74 residues are underscored. See Fig. 2B.
Figure 3. K8 S74A mutation inhibits K8 transamidation by TG2 in vitro. A) HT29 cells
were treated with vehicle or 1 M OA for 30 or 60 min. Treated cells were solubilized
in Nonidet P-40-containing buffer, then incubated with or without TG2 for 15 min
(37°C). Extracts were analyzed by blotting, using antibodies to K8, K8 pS74, and TG2.
TG2 blot (bottom panel) confirms the addition of exogenous TG2 to the designated
extracts. Note that hyperphosphorylation promotes K8-containing cross-link forma-
tion. B) BHK cells were transfected with WT K18 plus the indicated K8 constructs. After
48 h, cells were solubilized with Nonidet P-40, followed by TG2 reactions (15 min,
37°C) using the undiluted extracts or extracts diluted by 1/2 and 1/4. After
quenching, samples were separated by SDS-PAGE, followed by immune blotting using
anti-K8 antibodies to assess K8 cross-linking (indicated by bracket). Bottom panel
shows a lower exposure of the gel in order to demonstrate near-equal loading. C) BHK
cells were transfected with WT K18 plus the indicated K8 constructs. After 48 h, OA (1
M, 30 min) was added to the cultured cells, followed by detergent solubilization. Cell
extracts were either left untreated or treated with TG2 for 15 min (37°C), followed by
quenching, then analysis of K8 cross-links (indicated by bracket) by immunoblotting with an anti-K8 antibody. Bottom panel
shows a lower exposure of the gel in order to demonstrate near-equal loading for each dilution set. D) Primary hepatocytes
were isolated from K8 S74A and K8 WT transgenic mice; after 8 h of culture, hepatocytes were treated with either DMSO alone
or 1 M OA (45 min, 37°C). Cultured hepatocytes were then lysed in Nonidet P-40 buffer, and extracts were subjected to in
vitro transamidation. Middle panel shows human K8 expression (input) in the hepatocyte extracts. Bottom panel shows the
induction of S74 phosphorylation in WT K8 transgenic liver after OA treatment. Top panel shows K8 cross-linking (indicated
by bracket) before and after OA treatment.
2322 Vol. 26 June 2012 KWAN ET AL.The FASEB Journal  www.fasebj.org
K8 cross-linking but robust K8 cross-linking in extracts
from OA-treated cells (Fig. 3A). Although the HT29
extracts contain endogenous TG2 (Fig. 3A, bottom
panel, lanes 4–6), appreciable K8 cross-linking in the
cell extracts occurs only with the addition of recombi-
nant TG2, because cellular TG2 activity is tightly regu-
lated, and the enzyme is generally maintained in an
inactive state (45–47). Our data suggest that phosphor-
ylation at one or more Ser or Thr residues in K8
enhance its cross-linking, though phosphorylation of
other proteins may also promote their cross-linking
to K8.
To focus more specifically on K8 S74 phosphoryla-
tion and its potential role in K8 cross-linking, WT,
S74A, and S74D K8 cDNA constructs were transiently
transfected into BHK cells. In vitro transamidation of
transfected cell extracts showed similar cross-linking for
WT and S74A K8, while the phosphomimetic K8 S74D
had enhanced cross-linking (Fig. 3B). Next, we com-
pared the effect of the K8 S74 or Q70 mutation in
transfected BHK cells on the OA-mediated enhanced
transamidation that was observed in HT29 extracts. WT
K8 from OA-treated cells was efficiently cross-linked
after the addition of exogenous TG2 (Fig. 3C; compare
lanes 1 and 2). In contrast, the S74A mutation greatly
reduced the level of K8 cross-linking seen after OA
treatment with an even higher reduction for Q70N
mutation (Fig. 3C). Furthermore, K8 from cell extracts
of isolated hepatocytes from previously described trans-
genic mice that express K8 S74A (30, 48) also showed a
defect in TG2-mediated cross-linking in vitro as com-
pared to K8 from hepatocyte extracts from transgenic
mice that express WT K8 (Fig. 3D; compare lanes 1 and
2). In addition, hyperphosphorylation via exposure of
the cultured primary hepatocytes to OA enhanced in
vitro cross-linking of WT but not S74A K8. (Fig. 3D;
lanes 1 and 3 vs. 2 and 4).
K8 S74A mutation inhibits keratin cross-linking and
MDB formation in transgenic mice
We tested the importance of K8 S74 phosphorylation
on MDB formation and keratin cross-linking in vivo.
For this experiment, we compared susceptibility to
MDB formation in mice that overexpress WT or S74A
K8 along with mice that overexpress the human liver
disease-predisposing mutation K8 G62C, which causes a
conformational change that interferes with K8 S74
phosphorylation (30, 49). As expected, DDC feeding
resulted in a robust MDB response in WT K8 mice,
Figure 4. K8 S74A and K8 G62C transgenic mice have
impaired ability to form MDBs and K8 cross-links. A)
Nontransgenic (FVB) or transgenic mice that overexpress
K8 WT, K8 G62C, or K8 S74A in an FVB strain background
were fed DDC for 6 wk. Panel shows H&E-stained liver
sections that highlight MDBs (large arrows), hepatocyte
ballooning (dotted outline in the K8 WT panel), and
ductular proliferation (arrowheads). K8 WT livers showed
abundant MDB formation, which was greatly reduced in
K8 G62C and K8 S74A livers. Scale bar 
 100 m. B)
Frozen sections from livers of the indicated mouse lines
(DDC feeding) were stained for K8/K18 (green) and Ub
(red). K8/K18 and Ub-positive aggregates represent MDBs
(arrows). Note the MDBs in livers from K8 WT mice that
are significantly less abundant in K8 G62C and S74A livers (see Supplemental Table S1 for quantification). Top right panel
shows control staining that included the secondary fluorescent antibodies but not the primary anti-K8 and anti-Ub
antibodies. Scale bar 
 50 m. C) Equal liver protein homogenates from the indicated mouse lines were blotted with
antibodies to the indicated antigens. Each of the lanes represents an independent liver homogenate. Note that DDC
feeding results in increased levels of TG2. The HSP60 blot serves as a loading control.
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which are predisposed to MDB formation because of
K8 overexpression (11, 12) as compared with nontrans-
genic FVB mice (Fig. 4A, B and Supplemental Table
S1). In contrast, the MDB response (as determined by
H&E and immune staining) in the K8 S74A mice was
markedly inhibited while that of the K8 G62C mice was
also inhibited but to a lesser extent (Fig. 4A, B; Supple-
mental Table S1). In addition, K8 S74A transgenic
mouse liver sections contained significantly fewer bal-
looned hepatocytes, which are typically found in asso-
ciation with MDB formation (Supplemental Table S1).
Other aspects of DDC-induced hepatotoxicity were
assessed in the different mouse lines, including serum
alanine aminotransferase, alkaline phosphatase, and
total bilirubin (Supplemental Table S2), but we were
not able to link any observed differences to MDB
formation per se, given that the K8 G62C and S74A
mutations play several additional roles, such as predis-
position to apoptosis (30). Biochemical evidence of
MDB formation, or lack thereof, was also confirmed by
immunoblotting the liver homogenates with antibodies
to K8 and Ub, which demonstrated the presence of
K8/Ub-containing high-molecular weight complexes
primarily in K8 WT livers (Fig. 4C).
DISCUSSION
Our findings identify Q70 as the first K8 transamidation
site to be characterized, and provide evidence that
mutation of K8 Q70 significantly inhibits the ability of
K8 to be efficiently cross-linked by TG2 in cultured cells
and in vitro. Notably, findings herein show that K8 Q70
is a poor TG2 substrate unless the adjacent K8 S74
becomes phosphorylated, which occurs in the context
of liver injury. This scenario is consistent with the
observation that K8 S74 is phosphorylated in vivo by the
stress-activated kinases p38 (50) and JNK (51). K8 S74
phosphorylation plays several additional roles, includ-
ing a phosphate sponge role that endows K8/K18 the
ability to serve as stress proteins (30, 48) and a role
allowing K8 and K18 filaments to reorganize in re-
sponse to stress (50), which may expose several typically
masked K8 rod domain lysines to sumoylation during
oxidative stress and liver injury (52). Our model
(Fig. 5) suggests that K8 S-74 phosphorylation acts as a
switch that promotes TG2-mediated transamidation of
K8 Q70 (and possibly other glutamines), thus initiating
the process of K8 cross-linking and MDB formation.
Notably, K8 Q70 is conserved in all human type II
keratins and in mammalian K8 orthologs (rats, mice,
pigs, and cattle), thereby supporting its potential rele-
vance in the keratins that also have a K8 Ser74 equiva-
lent (53). Furthermore, K8 Ser74 is conserved in sev-
eral mammalian species (mice, humans, pigs, cattle,
and chimpanzees), but interestingly it is replaced by
Asn in rats, which can nevertheless develop MDBs in a
nonalcoholic steatohepatitis model (54). In the context
of rat K8, we hypothesize that other phosphorylation
sites that functionally mimic mouse and human K8 S74
are likely to be involved in MDB formation in rats.
Although our data suggest that Q70 might play an
important role in MDB formation, they do not pre-
clude the possibility that other K8 Gln/Lys might be
important for K8 cross-linking and MDB formation.
Interestingly, TG2 plays other cross-linking roles during
liver injury, including the inactivation of the transcrip-
tion factor Sp1 that, in turn, promotes apoptosis (55).
However, it is not known whether Sp1 phosphorylation
promotes cross-linking by TG2, and the potential role
of phosphorylation in the regulation of TG2 cross-
linking of its substrates is poorly understood. Taken
Figure 5. Model for K8 phos-
phorylation-modulated, TG2-me-
diated, K8 cross-linking, and
MDB formation. Unique types of
cell stress, such as DDC in mice
and alcohol in humans, cause
p38 and JNK kinase activation
and an increase in the K8 to K18
ratio in hepatocytes. Activated
p38 and JNK kinases, among oth-
ers, phosphorylate K8 S74 (and
S432, in addition to other poten-
tial sites represented by the label
P). K8 S74 phosphorylation ren-
ders K8 Q70 (and possibly other
Gln/Lys on K8 and other pro-
teins) a good TG2 substrate,
thereby leading to K8 cross-link-
ing to other MDB constituent
proteins. The increased K8 to
K18 ratio and increased TG2 lev-
els and activity in affected hepa-
tocytes also drive the equilibrium
toward K8 cross-linking andMDB
formation.
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together, our findings highlight a novel mechanism by
which phosphorylation controls TG2-mediated transami-
dation and inclusion formation.
The findings herein also have potential implications
for the pathogenesis of inclusions that have other IF
proteins as their major constituents and whose forma-
tion is poorly understood. Examples include desmin-
containing inclusions in some of the desminopathies
(56), glial fibrillary acidic proteins that form inclusions
termed Rosenthal fibers in Alexander disease (57), and
-internexin in neuronal intermediate filament inclu-
sion disease (58). It remains to be determined whether
phosphorylation and/or IF cross-linking via one or
more TGs play a critical role in the formation of these
inclusions.
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